USSTOCK.TODAY
Regular Market
Log in Sign up

Sellas Life Sciences Announces Successful Phase 3 Clinical Trial for Acute Myeloid Leukemia

Stocktwits +2 · ·by G4L

SLS
SLS SELLAS Life Sciences Group Inc
$7.47 -4.96%
View chart & analysis →
  1. 1Sellas Life Sciences announced that its pivotal Phase 3 Regal trial met its primary endpoint.
  2. 2GPS recorded a 41% reduction in the risk of death compared to best available therapy (BAT).
  3. 3SLS shares rose 7.1% in premarket trading.

So what's the key point?

Sellas Life Sciences achieved positive results in a leukemia treatment trial. The study reduced the risk of death by 41%, which may lead to a rise in the stock price.

Source Stocktwits +2 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →